You are here

A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bangalore, Karnataka, 560 038 India
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Contact Dermatitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- To be eligible for enrollment in this study, patients must be prescribed oral Medrol
tablets (4mg and 16 mg) for contact dermatitis as per the locally approved prescribing
information

- Medrol tablets, will be prescribed to the patient by the physician according to
his/her usual practice. The decision to prescribe Medrol tablet will necessarily
precede and will be independent of the decision to enroll patient into the study

- Only those patients, who are ready to sign an informed consent, will be included in
the study

- Subject can be contacted through telephone

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have any other dermatological or systemic condition that may interfere or
confound with the study outcome measurements

- Patients taking any oral steroid preparation or immunomodulators or have taken any
such oral medication during last 15 days before enrollment. NSAIDs (Non Steroidal
Anti-Inflammatory Agents) are excluded from the list

- Any contraindication to Medrol tablet use. Contraindications of Medrol use are
systemic fungal infections and known hypersensitivity to components

- Participation in other studies within last 1 month before the current study begins
and/or during study participation

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study

NCT00929981
Pfizer
Completed
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability of Medrol in treating contact dermatitis in Indian patients. Patients with contact dermatitis who have been prescribed for Medrol will be enrolled into the study and will be followed up for the resolution of symptoms
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients who have been prescribed oral Medrol Tablets (4 or 16 mg) for treatment of contact dermatitis will be enrolled
Dermatitis, Contact
Drug: Tablet Methylprednisolone (4 or 16 mg)
Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
Oral Methylprednisolone
Intervention: Drug: Tablet Methylprednisolone (4 or 16 mg)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • To be eligible for enrollment in this study, patients must be prescribed oral Medrol tablets (4mg and 16 mg) for contact dermatitis as per the locally approved prescribing information
  • Medrol tablets, will be prescribed to the patient by the physician according to his/her usual practice. The decision to prescribe Medrol tablet will necessarily precede and will be independent of the decision to enroll patient into the study
  • Only those patients, who are ready to sign an informed consent, will be included in the study
  • Subject can be contacted through telephone

Exclusion Criteria:

  • Patients who have any other dermatological or systemic condition that may interfere or confound with the study outcome measurements
  • Patients taking any oral steroid preparation or immunomodulators or have taken any such oral medication during last 15 days before enrollment. NSAIDs (Non Steroidal Anti-Inflammatory Agents) are excluded from the list
  • Any contraindication to Medrol tablet use. Contraindications of Medrol use are systemic fungal infections and known hypersensitivity to components
  • Participation in other studies within last 1 month before the current study begins and/or during study participation
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT00929981
B0121004
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now